Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1971 2
1972 1
1973 2
1975 3
1976 1
1977 3
1978 1
1979 1
1980 2
1981 13
1982 5
1983 6
1984 12
1985 13
1986 9
1987 8
1988 11
1989 21
1990 14
1991 20
1992 14
1993 10
1994 26
1995 27
1996 32
1997 24
1998 38
1999 37
2000 42
2001 39
2002 36
2003 33
2004 36
2005 42
2006 33
2007 28
2008 18
2009 30
2010 53
2011 57
2012 48
2013 51
2014 54
2015 49
2016 48
2017 58
2018 50
2019 62
2020 61
2021 79
2022 88
2023 71
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

1,400 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Peripheral epithelioid sarcoma"
Page 1
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18. J Clin Oncol. 2020. PMID: 32421444 Clinical Trial.
PURPOSE: To determine whether the administration of histology-tailored neoadjuvant chemotherapy (HT) was superior to the administration of standard anthracycline plus ifosfamide neoadjuvant chemotherapy (A+I) in high-risk soft tissue sarcoma (STS) of an extremity or the tr …
PURPOSE: To determine whether the administration of histology-tailored neoadjuvant chemotherapy (HT) was superior to the administration of s …
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. Spunt SL, et al. Lancet Oncol. 2020 Jan;21(1):145-161. doi: 10.1016/S1470-2045(19)30672-2. Epub 2019 Nov 27. Lancet Oncol. 2020. PMID: 31786124 Free PMC article.
BACKGROUND: Tumour grade, tumour size, resection potential, and extent of disease affect outcome in paediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), but no risk stratification systems exist and the standard of care is poorly defined. ...METHODS: In this prospec …
BACKGROUND: Tumour grade, tumour size, resection potential, and extent of disease affect outcome in paediatric non-rhabdomyosarcoma soft-tis …
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Lancet Oncol. 2017. PMID: 28499583 Clinical Trial.
Eligible patients were aged 18 years or older with localised, high-risk (high malignancy grade, 5 cm or longer in diameter, and deeply located according to the investing fascia), soft-tissue sarcoma of the extremities or trunk wall and belonging to one of five histological …
Eligible patients were aged 18 years or older with localised, high-risk (high malignancy grade, 5 cm or longer in diameter, and deeply locat …
Children's Oncology Group's 2023 blueprint for research: Bone tumors.
Reed DR, Grohar P, Rubin E, Binitie O, Krailo M, Davis J, DuBois SG, Janeway KA. Reed DR, et al. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30583. doi: 10.1002/pbc.30583. Epub 2023 Jul 27. Pediatr Blood Cancer. 2023. PMID: 37501549
The Children's Oncology Group (COG) Bone Tumor Committee is responsible for clinical trials and biological research on localized, metastatic, and recurrent osteosarcoma and Ewing sarcoma (EWS). Results of clinical trials in localized disease completed and published in the …
The Children's Oncology Group (COG) Bone Tumor Committee is responsible for clinical trials and biological research on localized, metastatic …
Dermatofibrosarcoma Protuberans in Children.
Sleiwah A, Wright TC, Chapman T, Dangoor A, Maggiani F, Clancy R. Sleiwah A, et al. Curr Treat Options Oncol. 2022 Jun;23(6):843-854. doi: 10.1007/s11864-022-00979-9. Epub 2022 Apr 8. Curr Treat Options Oncol. 2022. PMID: 35394606 Review.
While an excision technique that incorporates the deep fascia with a 3-cm peripheral margin is acceptable in adults, planning of the excision margin in children should involve consideration of preoperative imaging with MRI, site of the tumour, age, and physical built of th …
While an excision technique that incorporates the deep fascia with a 3-cm peripheral margin is acceptable in adults, planning of the …
microRNAs and Soft Tissue Sarcomas.
Fujiwara T, Kunisada T, Takeda K, Ozaki T. Fujiwara T, et al. Adv Exp Med Biol. 2015;889:179-99. doi: 10.1007/978-3-319-23730-5_10. Adv Exp Med Biol. 2015. PMID: 26659002 Review.
Soft tissue sarcomas are a highly heterogenous group of malignant tumors that originate from mesenchymal tissues including muscle, adipose and fibrous tissues, blood vessels, and peripheral nerves. A large variety of histological subtypes that current diagnostic approaches …
Soft tissue sarcomas are a highly heterogenous group of malignant tumors that originate from mesenchymal tissues including muscle, adipose a …
Management of pelvic sarcoma.
Lee JS, Kelly CM, Bartlett EK. Lee JS, et al. Eur J Surg Oncol. 2022 Nov;48(11):2299-2307. doi: 10.1016/j.ejso.2022.09.011. Epub 2022 Sep 17. Eur J Surg Oncol. 2022. PMID: 36195471
Soft tissue sarcomas of the pelvis include most commonly liposarcoma, leiomyosarcoma, gastrointestinal stromal tumors, malignant peripheral nerve sheath tumors, and solitary fibrous tumors. Bone sarcomas of the pelvis most commonly include osteosarcoma and chondrosarcoma. …
Soft tissue sarcomas of the pelvis include most commonly liposarcoma, leiomyosarcoma, gastrointestinal stromal tumors, malignant peripher …
Current management of benign retroperitoneal tumors.
Tirotta F, Napolitano A, Noh S, Schmitz E, Nessim C, Patel D, Sicklick JK, Smith M, Thway K, van der Hage J, Ford SJ, Tseng WW. Tirotta F, et al. Eur J Surg Oncol. 2023 Jun;49(6):1081-1090. doi: 10.1016/j.ejso.2022.07.006. Epub 2022 Jul 19. Eur J Surg Oncol. 2023. PMID: 35879135 Review.
A literature search using PubMed indexed articles was conducted and BRT were classified into five different biological subgroups: 1) lipomatous tumors, 2) smooth muscle tumors, 3) peripheral nerve sheath tumors, 4) myofibroblastic tumors, and 5) others. ...Specifically, th …
A literature search using PubMed indexed articles was conducted and BRT were classified into five different biological subgroups: 1) lipomat …
Clinical differences between central and peripheral chondrosarcomas.
Laitinen MK, Evans S, Stevenson J, Sumathi V, Kask G, Jeys LM, Parry MC. Laitinen MK, et al. Bone Joint J. 2021 May;103-B(5):984-990. doi: 10.1302/0301-620X.103B5.BJJ-2020-1082.R2. Bone Joint J. 2021. PMID: 33934657
Conventional chondrosarcoma may be central or peripheral. Most studies group central and peripheral chondrosarcomas together, although there is growing evidence that their clinical behaviour and prognosis differ. ...CONCLUSION: Both central and peripheral cho …
Conventional chondrosarcoma may be central or peripheral. Most studies group central and peripheral chondrosarcomas together, …
Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma.
Mack T, Purgina B. Mack T, et al. Curr Oncol. 2022 Sep 7;29(9):6400-6418. doi: 10.3390/curroncol29090504. Curr Oncol. 2022. PMID: 36135073 Free PMC article. Review.
Correct tumor classification has become important for prognostication and the evolving targeted therapies for sarcoma subtypes. In this review, the pathology of retroperitoneal soft tissue sarcomas is discussed, which is important to the surgical oncologist. In addition, l …
Correct tumor classification has become important for prognostication and the evolving targeted therapies for sarcoma subtypes. In th …
1,400 results